Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed as a Director and Chief Executive Officer in late 2021. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.
Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Dr. Greenstreet serves on the board of directors of Pacira BioSciences, Inc., argenx SE and The American Funds. Additionally, she is in the Scientific Advisory Committee of the Bill and Melinda Gates Foundation, a member of the Discovery Council of Harvard Medical School and a member of Biotechnology Industry Organization (BIO) Health Section Governing Board (HSGB).
Dr. Akshay Vaishnaw joined Alnylam Pharmaceuticals in 2006 as VP Clinical Research and has then subsequently served in various R&D roles with increasing responsibility. Akshay was promoted to President of R&D in March of 2018 and was appointed as President of Alnylam in January of 2022. Prior to 2006, he was at Biogen as Senior Director, Translational Medicine.
Akshay received his M.D. from the University of Wales College of Medicine, U.K., and Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra, Inc.
Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam.
Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.
Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ).
Jeff Poulton joined Alnylam as CFO in August 2019. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US.
Between 2003 and December 2017, Jeff held various roles of increasing responsibility at Shire Plc, culminating in his service as Chief Financial Officer and a member of Shire’s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Jeff also led Shire’s rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Jeff led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp and PPG Industries. Jeff also served in the United States Navy as a Commissioned Officer.
Jeff holds a BA in Economics from Duke University and an MBA in Finance from the Kelley School of Business at Indiana University. He is a member of the Board of Directors of EIP Pharmaceuticals and Homology Medicines.
Kelley Boucher joined Alnylam in 2019 bringing nearly 20 years of experience within the biotechnology and medical device industries. She oversees the global HR organization which includes talent planning & strategy, organizational effectiveness, talent acquisition, learning & development, total rewards, and HR systems.
Prior to Alnylam, Kelley served as Vice President and Global Head of Human Resources at Abiomed for three years as the company experienced exponential growth and commercial execution. Before her time at Abiomed, Kelley spent 10 years at Shire where she held a variety of roles across HR, eventually becoming Vice President and Head of Human Resources for Technical Operations and then Shire’s Corporate Divisions. She also managed the organizational design component of multiple acquisitions. Prior to Shire, Kelley was a Principal Consultant at Clockwork Consulting (a pharmaceutical recruitment firm) and worked at Syntonix Pharmaceuticals (acquired by Biogen) and Digitas. She was honored with the Healthcare Business Women’s Association Rising Star award in 2013. Kelley is a member of the Healthcare Business Women’s Association (HBA), the Human Resources Leadership Forum (HRLF) and the Corporate Executive Board (CEB).
Kelley attended Cornell University where she received her Bachelor of Arts in government relations and the Darden School of Business at the University of Virginia where she completed her studies in the Strategic Leadership Development executive program.
Dr. Alfred “Al” Boyle joined Alnylam in 2015 with over 20 years of experience within the biotechnology, pharmaceutical and chemical industries. He leads a team accountable for all aspects of CMC development, clinical and commercial product manufacturing and supply, enterprise GxP Quality oversight and facilities and engineering operations globally.
Prior to joining Alnylam, Al served as Vice President of Global Technical Services at Alexion Pharmaceuticals where he was responsible for technology transfer and process oversight of cGMP manufacturing of clinical and commercial products. Prior to this role, Al served as Vice President, Technical Operations in Switzerland and Ireland also with Alexion. For this position, he led an organization in Switzerland accountable for business, technical and quality oversight of drug substance, drug product and finished product contract manufacturing organizations; and led the relocation of this organization to Ireland. Prior to Alexion, Al spent over eight years with Bristol-Myers Squibb, overseeing fermentation and biocatalysis development, technology transfer and commercial manufacturing support of biologics products. He also held positions in the Research and Development functions of Celgene Corporation, Akzo-Nobel and Hercules Inc.
Dr. Boyle obtained his Bachelor of Science and Master of Science degrees from the State University of New York College of Environmental Science and Forestry and a Ph.D. in Microbiology from Rutgers University.
Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. He has worked across multiple geographies including the U.S., Europe, and emerging markets and in a broad range of small and large disease therapy areas.
Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure.
Tolga received his Bachelor of Science in Finance and Economics from Istanbul University in Turkey and his MBA in Marketing and Supply Chain Management from Michigan State University, as well as a post graduate certificate in Marketing from the University of California, Santa Barbara.
Indrani Franchini joined Alnylam in January 2022 and has over 20 years of global legal experience in a variety of legal and compliance roles. She has held multiple leadership positions providing legal, government investigations, regulatory, governance, privacy, quality, compliance and commercial contracting counsel to a broad range of global functions.
Prior to joining Alnylam, Indrani served as Executive Vice President, Chief Compliance Officer at Alexion, and was a member of the executive team. Over her four years in this role, Indrani built and led a 300+ person global organization focused on risk management, including compliance, quality, and all aspects of policy, training, reporting, internal and external investigation, and communication.
Prior to Alexion, Indrani spent five years in legal and compliance roles functioning as Chief Compliance Officer and Assistant Corporate Secretary for Hess Corporation, a Fortune Global 500 leader in oil and gas exploration and production. Before Hess, Indrani spent almost ten years at Pfizer in various positions, including supporting the Global Pharmaceutical business. She began her career practicing corporate and transactional law at Milbank LLP, where she spent six years working in their New York and Tokyo offices.
Indrani received her Bachelor of Arts from Princeton University, her Juris Doctorate from the University of Michigan Law School, and served as a Fullbright Fellow at Kyushu University Graduate School in Fukuoka, Japan.
Board of Directors
The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA interference) therapeutics.
MICHAEL W. BONNEY
Executive Chair, and former Executive Chair and Chief Executive Officer of Kaleido Biosciences; Board Chair of Magenta Therapeutics; Director of Bristol Myers Squibb Company; former Chief Executive Officer and Director of Cubist Pharmaceuticals; and former Director of Sarepta Therapeutics and Syros Pharmaceuticals.
DENNIS A. AUSIELLO,
Director of the Center for Assessment Technology and Continuous Health (CATCH); Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Physician‐in‐Chief Emeritus at Massachusetts General Hospital; Member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences; Director of Seres Therapeutics and Rani Therapeutics.
Senior Advisor at Blackstone Group, former Chief Executive Officer and Director of Sanofi, former Chief Executive Officer and Chair of Bayer HealthCare, former President and General Manager of the Emerging Markets and Established Products business units, and member of the Executive Leadership Team of Pfizer Inc.
MARSHA H. FANUCCI
Former Chief Financial Officer of Millennium Pharmaceuticals; Chair of the Board of Directors of Cyclerion Therapeutics; Director of Syros Pharmaceuticals and Forma Therapeutics.
Chief Executive Officer of Alnylam, Member of the Board of Directors of Pacira BioSciences, Inc., argenx SE and The American Funds, Scientific Advisory Committee of the Bill and Melinda Gates Foundation, member of the Discovery Council of Harvard Medical School and a member of Biotechnology Industry Organization (BIO) Health Section Governing Board (HSGB).
MARGARET A. HAMBURG,
Former Commissioner of the U.S. Food & Drug Administration (FDA); Interim Vice President, Global Biological Policy and Programs at the Nuclear Threat Initiative; former Foreign Secretary of the National Academy of Medicine (NAM); and former Chair of the Board of the American Association for the Advancement of Science (AAAS).
DAVID E.I. PYOTT
Former Chair and Chief Executive Officer of Allergan; Member of the Supervisory Board of Royal Philips in the Netherlands; Director of BioMarin Pharmaceutical and Pliant Therapeutics, former Lead Director of Avery Dennison Corporation.
COLLEEN F. REITAN
Former President of Plan Operations and Chief Operating Officer of Health Care Service Corporation (HCSC); former President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota. Director of Myriad Genetics and Cricket Health.
AMY W. SCHULMAN,
Managing Partner, Polaris Partners; Co-founder, Executive Chair, and former Chief Executive Officer of Lyndra Therapeutics; Executive Chair of SQZ Biotech; Senior Lecturer at Harvard Business School; former Executive Vice President and General Counsel of Pfizer; served as the Business Unit Lead for Pfizer Consumer Healthcare.
PHILLIP A. SHARP,
Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Founding Director of McGovern Institute for Brain Research, MIT; Nobel Laureate; Founder of Alnylam; Co-founder and former Director of Biogen; Member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences; Director of Syros Pharmaceuticals and Vir Biotechnology.